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Abstract
Background: Mutations in the progranulin gene (GRN) are the most common cause of frontotemporal lobar
degeneration with TDP-43 inclusions (FTLD-TDP). TDP-43 pathology is characterized by the hyperphosphorylation of
the protein at Serine 409/410 residues. Casein kinase-1δ (CK-1δ) was reported to phosphorylate TDP-43 directly.
Previous works from our laboratory described the presence of CDK6/pRb-dependent cell cycle alterations, and cytosolic
accumulation of TDP-43 protein in lymphoblast from FTLD-TDP patients carriers of a loss-of function mutation in GRN
gene (c.709-1G > A). In this work, we have investigated the effects of two brain penetrant CK-1δ inhibitors (IGS-2.7 and
IGS-3.27) designed and synthetized in our laboratory on cell proliferation, TDP-43 phosphorylation and subcellular
localization, as well as their effects on the known nuclear TDP-43 function repressing the expression of CDK6.
Results: We report here that both CK-1δ inhibitors (IGS-2.7 and IGS-3.27) normalized the proliferative activity of PGRN-
deficient lymphoblasts by preventing the phosphorylation of TDP-43 fragments, its nucleo-cytosol translocation and the
overactivation of the CDK6/pRb cascade. Moreover, ours results show neuroprotective effects of CK-1δ inhibitors in a
neuronal cell model of induced TDP-43 phosphorylation.
Conclusions: Our results suggest that modulating CK-1δ activity could be considered a novel therapeutic approach for
the treatment of FTLD-TDP and other TDP-43 proteinopathies.
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Background
Frontotemporal lobar degeneration (FTLD) is the primary
cause of early onset dementia after Alzheimer’s disease
(AD) and it is characterized by progressive alterations in
behaviour, personality and language [1–3]. Mutations in
tau (MAPT) and progranulin (GRN) genes and a repeat
expansion in C9orf72 are the most common genetic
alterations observed in FTLD patients [4–7]. Histochemi-
cally, FTLD can be subdivided according to the major
component of the protein inclusions deposited in the
brain. Around 50 % of the patients can be assigned to the
subgroup named FTLD-TDP, because the pathological
protein present in the inclusions is TDP-43 (transactive
response DNA-binding protein 43 KDa). In the most of
the cases, FTLD-TDP is associated with GRN mutations
[4, 5]. Deposition of TDP-43 has been also been detected
in some patients with amyotrophic lateral sclerosis (ALS)
[8], in consonance with the fact that these two diseases
share some clinical and genetic features such as mutations
the in TARDBP, FUS and C9orf72 genes [9].
TDP-43 is an evolutionarily conserved nuclear protein
that can bind to DNA and RNA, repress transcription,
and initiate exon skipping [10]. Under physiological con-
ditions TDP-43 is a predominantly nuclear protein. Its
pathology is characterized by hyperphosphorylation,
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ubiquitination, cleavage of C-terminal fragments, and
nucleus-to-cytoplasm translocation [8, 11], and its patho-
genesis may involve both loss of normal function in the
nucleus and toxic gain of function in the cytoplasm [12].
The phosphorylation of TDP-43 at tandem serines 409
and 410 characterizes all TDP-43 proteinopathy cases
and therefore it is considered a hallmark of pathological
TDP-43 [13, 14]. It is known that phosphorylation of site
Ser 409/410 of TDP-43 leads to oligomerization and fi-
bril formation in vitro [13]. Phosphorylation of TDP-43
may also play a role inhibiting the ubiquitin–proteasome
system mediated degradation, contributing to the forma-
tion of aggregates [15]. On the other hand, the mutation
of serines 409 and 410 to aspartic acid reduces the TDP-
43 aggregation [16].
Casein kinases 1 and 2 (CK-1 and CK-2) were shown to
phosphorylate TDP-43 in vitro [13]. However, antibodies
raised against TDP-43 label in histological sections of
FTLD and ALS brains show strong reactivity only for
phosphorylated epitopes generated by CK-1 [13]. In
addition, it was demonstrated that the products of CK-1
phosphorylation in vitro had similar electrophoretic
mobility than hyperphosphorylated TDP-43 present in
brain inclusions in FTLD patients [17]. Together, these
observations suggest that CK-1-mediated TDP-43
phosphorylation play a role in disease pathogenesis.
CK-1 is a Ser/Thr protein kinase that is ubiquitously
expressed in eukaryotic organisms [17]. At least seven
isoforms (α, β, γ1 − 3, δ, and ε) and various splice vari-
ants have been characterized in different organisms [18].
Among them, CK-1δ has been determined to phosphor-
ylate many different sites on TDP-43 in vitro [19].
Recently, we have developed a number of potent, very
selective and brain permeable CK-1δ inhibitors. These
compounds are benzothiazolyl derivatives that showed a
selectivity index “S” score of 0.04 after being tested on a
wide panel of more than 450 different protein kinases
[20]. We have demonstrated that CK-1δ inhibition pre-
vents TDP-43 phosphorylation in vitro decreasing its
neurotoxicity in drosophila models [20]. The present
work was undertaken to further explore the potential of
these CK-1δ inhibitors to overcome main pathologic
features of cells derived from FTLD-TPD patients. Our
previous work highlighted the role of the CDK6/pRb
pathway controlling cell fate survival/death of lympho-
blasts from carriers of a loss-of-function GRN mutation,
c.709-1G > A [21, 22]. It was suggested that an aberrant
activation of this cascade could have pathogenic signifi-
cance in PGRN deficiency-linked FTLD, as it is believed
that unscheduled cell cycle entry underlies neuronal loss
in neurodegenerative disorders [23–26]. The re-entry of
quiescent neurons into the cell cycle may result in a mi-
totic failure and cell death [27–29]. Moreover, we found
accumulated TDP-43 in the cytoplasm of these PGRN-
deficient lymphoblasts [21, 30]. Therefore, it appears
that these cell lines from patients, easily accessible, could
represent a suitable platform to search novel disease-
modifying drugs. Here, we report the effects of two
brain penetrant CK-1δ inhibitors, (IGS-2.7 and IGS-
3.27), in TDP-43 phosphorylation levels, cytoplasmic
TDP-43 accumulation, loss of TDP-43 nuclear func-
tion, and proliferative activity of immortalized lym-
phocytes from FTLD-TDP patients. Both compounds
were able to normalize the aberrant cell cycle control
and pathological distribution of TDP-43 of PGRN de-
ficient lymphoblasts. Furthermore, our results show a
neuroprotective effect of these drugs in a neuronal
model of induced TDP-43 phosphorylation. Finally, an
in vivo pharmacokinetic study of IGS-2.7 confirms
the brain penetration in mice after i.p. and oral ad-
ministration. It is suggested that these drugs can be
considered promising candidates for novel treatments
for FTLD associated to GRN mutations and others
pathologies in which TDP-43 is involved.
Results
Effects of CK-1δ inhibitors on proliferation of lymphoblasts
from control and c.709-1G > A GRN mutation carriers
individuals
Previous work from this laboratory demonstrated that
lymphoblasts derived from carriers of a loss-of-function
GRN mutation (c.709-1G > A), asymptomatic or FTLD
patients, show higher proliferative activity compared
with control lymphoblasts, that is associated with in-
creased levels of CDK6 protein [21, 22]. In addition,
these lymphoblastoid cell lines display enhanced
accumulation of cytosolic TDP-43, a hallmark of FTLD-
TDP disease [22, 30]. The TDP-43 protein present in the
brain deposits in FTLD-TDP patients is highly phosphory-
lated [8], being CK-1δ kinase involved in phosphorylation
of the molecule [13, 19]. On these grounds, we sought to
elucidate whether newly designed CK-1δ inhibitors
are able to normalize the distinct features of PGRN
deficient lymphoblasts. First, we carried out dose-response
experiments to evaluate the influence of increasing
concentrations of two N-benzothiazolyl-2-phenyl-acet-
amides derivatives (IGS-2.7 and IGS-3.27) on viability of
lymphoblasts from control and carriers of GRN mutation,
asymptomatic and FTLD-TDP patients. As shown in
Fig. 1a, both compounds decreased cell viability, assessed
by the MTT assay, in a dose-dependent manner although
with higher sensitivity in lymphoblasts from PGRN
deficient lymphoblasts. Further experiments were carried
out at 5 μM. The proliferative activity of control and
PGRN deficient lymphoblasts was measured by total cell
counting after treating cells with either 5 μM IGS-2.7 or
IGS-3.27 for 72 h (Fig. 1b). As is shown in Fig. 1b, the
addition of IGS-2.7 and IGS-3.27 abrogated the
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Fig. 1 Effects of CK1-δ inhibitors on the proliferation of lymphoblasts from control and c.709-1G > A GRN mutation carriers individuals. Immortalized
lymphocytes from control and carriers of a GRN mutation, asymptomatic or FTLD-TDP patients were seeded at an initial density of 1 × 106 × ml−1 in
the absence or in presence of two CK1-δ activity inhibitors, IGS-2.7 and IGS-3.27, for 72 h. a For the MTT assay a total of 100,000 cells per well were
seeded in a 96-well plate in presence of increasing doses (0–20 μM) of both drugs. Results represent the % of cell survival of treated cells referred to
untreated ones. b Effect of the treatment with IGS-2.7 and IGS-3.27 (5 μM) on proliferation of control and PGRN deficient lymphoblasts. Aliquots were
taken for cell counting 72 h after the drug administration. Data shown are the mean ± SEM of 6 independent experiments carried out with all the cell
lines used in this studio (**p < 0.01 significantly different from control cells. ††p < 0.01 significantly different from untreated cells; †p < 0.01 significantly
different from untreated cells)
Fig. 2 Cell cycle analysis of control and FTLD-TDP lymphoblast after treatment with CK1-δ inhibitors. Immortalized lymphocytes from control and
GRN mutation-related FTLD individuals were seeded at an initial density of 1 × 106 × ml−1 and cultured in RPMI medium in absence or presence
of IGS-2.7 and IGS-3.27 (5 μM). 36 h after drugs addition, cells were harvested, fixed, and analyzed by flow cytometry as described under Methods.
The mean ± SEM of the percentage of cells in the different cell cycle phases of four independent experiments is indicated for each condition
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enhanced proliferative response of PGRN deficient
cells, affecting in a lesser extent the proliferation of
control cells. Since the change in cell number de-
pends on the balance between cell proliferation and
cell death, we tested whether the CK-1δ inhibitors in-
duced cell death by necrosis/apoptosis. For this pur-
pose, we analyzed the distribution of cells in the cell
cycle phases. We did not observe statistically signifi-
cant changes in the proportion of subG1 hypodiploid
cells, characteristic of apoptosis/necrosis, in control
and PGRN deficient lymphoblasts after IGS-2.7 or
IGS-3.27 treatment (Fig. 2). Together, these results
suggest that the decreased cell number in cultures of
lymphoblasts from GRN mutation c.709-1G > A car-
riers in the presence of CK-1δ inhibitors truly reflects
a decrease in cell proliferation.
Effects of CK-1δ inhibitors on TDP-43 phosphorylation
The effects of IGS-2.7 and IGS-3.27 in decreasing TDP-
43 phosphorylation in control and mutant GRN cells
were assessed by Western blotting using a phospho-
specific (S409/410) anti-TDP-43 antibody. Figure 3a
shows a representative immunoblot. This antibody rec-
ognizes two major bands that appear in 43 KDa and 30
KDa of molecular weight. The smaller appears to be the
cleaved C-terminal region. An increase in the phosphor-
ylation levels of TPD-43 is clearly observed in the
cleaved region of the protein (30 KDa) in lymphoblast
from PGRN-deficient cells (Fig. 3a). Treatment with
5 μM of either IGS-2.7 or IGS-3.27 resulted in a signifi-
cant decrease in the levels of phosphorylation of TDP-43
that is more evident in PGRN-deficient lymphoblasts
(Fig. 3a, lower right panel). As indicated in Fig. 3b, there
Fig. 3 Effects of CK-1δ inhibitors on TDP-43 phosphorylation. Immortalized lymphocytes from control and GRN mutation-related FTLD individuals
were seeded at an initial density of 1 × 106 × ml−1 in absence or presence of IGS-2.7 and IGS-3.27 (5 μM). 24 h after drugs addition, cells were
harvested and processed for Western blotting analysis. a Representative immunoblot showing the effect of both CK-1δ inhibitors decreasing the
phosphorylation status of truncated (30KD) TDP-43 in PGRN deficient lymphoblasts. The plots bellow represent the quantifications of the bands of
43 KD (left) and 30 KD (right) of pTDP-43 normalized by Total-TDP-43. b The image represents the levels of total TDP-43 protein in control and
FTLD-TDP patients (left panel). Quantification of the TDP-43 band normalized with the β-tubulin levels is presented in the right panel. The
densitometric analyses represent the mean ± SEM of different observations carried out in four cell lines from each group (*p < 0.05 significantly
different from control cells. †p < 0.05 significantly different from untreated cells)
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were not differences in total TDP-43 levels between
control and mutant lymphoblasts before and after the
treatment with the CK-1δ inhibitors.
Effects of CK-1δ inhibitors on subcellular localization of
TDP-43
Since it has been suggested that phosphorylation of
TDP-43 may disrupt the balance between cytosolic and
nuclear TDP-43 localization, we were interested in
elucidating whether these CK-1δ inhibitors were able to
normalize the cytosolic TDP-43 accumulation, charac-
teristic of PGRN-deficient lymphoblasts [22, 30]. To this
end, we carried out fractionation of cell extracts after
the treatment with the corresponding CK-1δ inhibitor,
and processed them for Western blotting with an anti-
TDP-43 antibody. Our results shown that, as expected,
PGRN deficient lymphoblast present increased levels of
TDP-43 in the cytosolic fraction that paralleled lower
nuclear content of the protein compared with lympho-
blast form control individuals (Fig. 4a, b). Both treat-
ments with IGS-2.7 and IGS-3.27 were able to decrease
the levels of cytosolic TDP-43, preventing the exit of
TDP-43 from the nucleus in PGRN deficient cells with-
out affecting TDP-43 levels in control cells (Fig. 4a, b).
The influence of CK-1δ inhibitors on the subcellular
distribution of TDP-43 was further assessed by immuno-
staining using confocal microscopy. In agreement with
previous work from this laboratory [22], TDP-43 pre-
dominantly localizes in the nucleus (Fig. 5), although
low levels of TDP-43 are observed in the cytosol of con-
trol cells. Quantification of TDP-43 fluorescence clearly
indicates that cytosolic levels of TDP-43 are increased in
PGRN-deficient cells, and the addition of both IGS-2.7
and IGS-3.27 clearly favors nuclear retention of the pro-
tein (Fig. 5). Taken together, these results suggest that
phosphorylation of TDP-43 plays an important role in
favoring the exit of TDP-43 from the nucleus, and that
CK-1δ inhibitors contribute to normalize the aberrant
cytosolic TDP-43 accumulation in PGRN-deficient cells.
Effects of CK-1δ inhibitors on CDK6 expression levels
Since TDP-43 can repress CDK6 expression [31] and
CDK6/pRb pathway was found to be stimulated in
lymphoblast from carriers of GRN mutation [22], we
suggested that the increased expression of CDK6 in
PGRN deficient lymphoblast, could be the result of a
loss of function of TDP-43 repressing the CDK6 mRNA
expression, secondary to changes in the nuclear content
of TDP-43 [22]. For these reasons, we have evaluated
the effects of IGS-2.7 and IGS-3.27 on both CDK6
mRNA and protein levels of control and PGRN-deficient
lymphoblasts. Figure 6 shows that, as expected, CDK6
mRNA and protein levels were enhanced in PGRN-
deficient lymphoblasts. Both CK-1δ inhibitors were able
to decrease the expression of CDK6 mRNA (Fig. 6a) and
the protein levels (Fig. 6b).
CK-1δ inhibitors rescue neuroblastoma cells from death
induced by ethacrynic acid-mediated phosphorylation of
TDP-43
To validate the results obtained in non-neuronal cells
from FTLD-TDP patients, we tested the effects of IGS-2.7
Fig. 4 Effects of CK-1δ inhibitors on the subcellular localization of TDP-43 of control and GRN mutation lymphoblasts. Control and GRN mutation
carrier lymphoblasts were seeded at an initial density of 1 × 106 cells × ml−1 and incubated in presence or absence of IGS-2.7 and IGS-3.27 (5 μM)
for 24 h. After treatment, lymphoblasts were collected and lysed to obtain the cytosolic (a) and nuclear (b) fragments that were analyzed by
Western blotting. α-tubulin and LaminB1 antibodies were used as loading and purity control of the cytosolic and nuclear fractions respectively. A
representative experiment is shown. Densitometric analyses represent mean ± SEM of different observations carried out in seven cell lines from
each group (*p < 0.05 significantly different from control cells. †p < 0.05 significantly different from untreated cells)
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and IGS-3.27 in a neuronal cell model of induced TDP-43
phosphorylation by ethacrynic acid (EA) treatment [32]
Human neuroblastoma SH-SY5Y cells were preincubated
with the CK-1δ inhibitors, and then treated with 20 μM
EA for 12 h. As shown in Fig. 7a, the addition of EA to
the SH-SY5Y cells resulted in significant cell death, which
is partially prevented by the CK-1δ inhibitors treatment.
In Fig. 7b the effects of CK-1δ inhibiting the EA-
dependent TDP-43 phosphorylation are shown. To eluci-
date whether cell cycle-related events were involved in the
cell death induced by increased TDP-43 phosphorylation
driven by EA, we determined the levels of CDK6 in the
absence or in the presence of CK1-δ inhibitors. As it is
shown in Fig. 7c, the pretreatment with CK1-δ inhibitors
blunted the increase of CDK6 protein levels observed after
EA addition. Together, these results add further support
to the involvement of cell cycle dysregulation in neuronal
fate. Finally, data in Fig. 8 suggest that phosphorylation of
TDP-43 determines the subcellular localization of the pro-
tein. It is shown that both CK-1δ inhibitors, IGS-2.7 and
IGS-3.27, are able to prevent cytosolic TDP-43 accumula-
tion in EA-treated SH-SY5Y neuroblastoma cells (Fig. 8).
The CK-1δ inhibitor IGS-2.7 shows brain penetration
in vivo
To assess the drug-like properties of these compounds
such oral absorption and brain distribution, a pharmaco-
kinetic in vivo study of CK-1δ inhibitor IGS-2.7 in mice,
was performed. IGS-2.7 was administered i.p and p.o. to
mice at a dose of 2 and 10 mg.Kg−1, respectively. Blood
samples were collected at different times and immedi-
ately after, brain samples were also collected from each
mouse at the same times. Pharmacokinetic parameters
were calculated using a non-compartmental analysis
tool. The overall pharmacokinetic parameters summa-
rized in Table 1 show that following a single i.p. dose
Fig. 5 Confocal microscopy analysis of the subcellular localization of TDP-43 after CK-1δ inhibitors treatment of lymphoblast from control and
FTLD-TDP patients. Lymphoblasts were seeded at 106 cells × ml−1 and incubated in presence or absence of IGS-2.7 and IGS-3.27 (5 μM) for 24 h.
TDP-43 protein localization was assessed by confocal laser scanning microscopy. Cells were stained with anti- TDP-43 antibody followed by
secondary antibody labeled with Alexa Fluor 488. DAPI was included in the mounting media to stain the nucleus. Merged images show that the
treatment with both drugs prevent the higher cytosolic localization of TPD-43 protein in FTLD-TDP patients. Quantitative analyses of TDP-43
redistribution are shown in the right panel. Relative fluorescence intensity of TDP-43 inside and outside nuclei was determined in 18 cells from
four different fields in each condition. Magnification (63x). Values shown are the mean ± SEM. (**p < 0.01 significantly different from control cells.
††p < 0.01 significantly different from FTLD untreated cells)
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administration, brain concentration were detected up
to 24 h being the brain to plasma exposure ratio
2.03. Moreover, after a single oral dose administra-
tion, IGS-2.7 concentrations were detected both in
plasma and brain. In that case, the brain-to-plasma
exposure ratio was 3.58. These data show the good
pharmacokinetic profile of CK-1δ inhibitor IGS-2.7
that crosses perfectly the blood brain barrier and can
be orally administered.
Discussion
To date there is no specific pharmacological treatment
for FTLD-TDP, being the most frequently occurring
dementia in the presenile population. In the majority of
the cases it is associated with mutations in the GRN
gene. The study of PGRN haploinsufficiency and its
influence altering important signaling pathways, as well
as the insights into pathological processing of TDP-43
open new avenues for the identification of appropriated
targets and the discovery of effective drugs.
Previously we described a cell cycle control failure in
lymphoblasts from FTLD patients harboring a single
pathogenic splicing mutation in the GRN gene (c.709-
1G > A) [22]. The enhanced proliferative activity of
PGRN deficient cells was accompanied by accumulation
of TDP-43 in the cytosolic compartment [22, 30]. There-
fore we concluded that these lymphoblastoid cell lines
from FTLD-TDP patients could be a useful platform to
test novel disease-modifying drugs, as they recapitulate
at least two pathogenic mechanisms thought to be in-
volved in the neurodegenerative process in FTLD, such
as reactivation of cell cycle and alteration of TDP-43
subcellular distribution.
TDP-43 pathological processing includes translocation
from nucleus to cytoplasm, truncation, hyperphosphory-
lation and ubiquitination. It is believed that abnormal
phosphorylation of TDP-43 at the Ser 409/410 is a crit-
ical step in FTLD-TDP and other neurodegenerative dis-
eases such as amyotrophic lateral sclerosis (ALS) [8, 33]
Alzheimer’s disease (AD) [34], and Parkinson’s disease
(PD). Since it was reported that CK-1δ is likely to be
involved in TDP-43 phosphorylation in vivo [13], the
search for specific inhibitors of this enzyme has become
a challenge for the treatment of these proteinopathies
[35]. Recently, we developed a number of potent CK-1δ
inhibitors able to prevent TDP-43 phosphorylation
in vitro and neurotoxicity in vivo [20]. Two of these ben-
zothiazolyl amides, named IGS-2.7 and IGS-3.27 are able
to cross the BBB with IC50 values in the nM range and
great selectivity on a panel of more than 450 different
kinases. Here we have evaluated the efficacy of these two
drugs in normalizing the survival pattern of lympho-
blasts harboring a loss-of-function GRN mutation. These
lymphoblastoid cell lines were previously obtained from
patients of FTLD-TDP and asymptomatic individuals
with the mutation. For this purpose, we investigated the
effects of these two drugs on the increased proliferative
activity, TDP-43 phosphorylation, TDP-43 cytosolic ac-
cumulation, as well as their effects on CDK6 expression
levels. These are distinct features of these PGRN-
deficient lymphoblastoid cell lines [22, 30]. Moreover
the potential neuroprotective role of these CK-1δ inhibi-
tors was studied in a neuronal cell model of induced
TDP-43 phosphorylation driven by ethacrynic acid
Fig. 6 Effects of CK-1δ inhibitors on CDK6 expression levels.
Immortalized lymphocytes from control and c.709-1G > A GRN
mutation carriers, were seeded at an initial density of 1 × 106 × ml−1
and cultured in RPMI medium containing 10 % FBS in the absence
or in the presence of IGS-2.7 and IGS-3.27 (5 μM). 24 h later cells
were harvested to isolate RNA and to prepare cell lysates. a) CDK6
mRNA expression levels were analyzed by quantitative RT-PCR. Data
shown are the mean ± SEM of different observations using five
controls, five asymptomatic and five FTLD-TDP patients.
b) Representative immunoblot showing CDK6 protein content after
drugs treatment. Densitometric measurements were performed on
individual immunoblots and values indicate the mean of CDK6 levels
normalized with the corresponding β-actin levels ± SEM for experiments
carried out with seven different cell lines for each group (*p < 0.05 and
**p < 0.01 significantly different from control cells; †p < 0.05 and
††p < 0.01 significantly different from untreated cells)
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treatment [32]. Our results show that IGS-2.7 and IGS-
3.27 prevented the enhanced serum-mediated prolifera-
tion of PGRN deficient lymphoblasts, affecting very little
the normal basal rates of proliferation in control cells.
Moreover these CK-1δ inhibitors blunted the stimulated
CDK6 protein and transcript levels observed in mutant
lymphoblasts, thus providing an explanation for the anti-
proliferative effect of these drugs. At the doses used in
the proliferative experiments, both IGS-2.7 and IGS-3.27
inhibited significantly the endogenous TDP-43 phos-
phorylation. Interestingly, the inhibition of TDP-43
phosphorylation was accompanied by reduced cytosolic
TDP-43 accumulation in lymphoblasts carrying the GRN
mutation. Taken together these results suggest that CK-
1δ-mediated phosphorylation of TDP-43 may play an
important role in controlling the trafficking of TDP-43
protein from the nucleus to the cytosol. This finding is
in consonance with previous work showing similar
effects of inhibitors of cyclin-dependent kinases (CDKs)
on cytosolic TDP-43 accumulation [36]. It is worth to
highlight the apparent relationship between TDP-43
phosphorylation, cytosolic TDP-43 accumulation, and
cell cycle regulatory proteins. Our data showing that the
PGRN deficiency-induced increased proliferative activity
and CDK6 levels are accompanied by TDP-43 cytosolic
accumulation, and the previous reports showing the
involvement of cell division cycle 7 (CDC7) kinase on
TDP-43 pathology [37] provide further support to the
idea that altered cell cycle regulatory proteins may play a
role in abnormal TDP-43 processing under pathological
conditions.
The important question as to whether cytosolic
TDP-43 accumulation implicates the gain of a new
toxic function for TDP-43 and/or the concomitant
reduced TDP-43 nuclear levels may represent the loss
of an essential function, cannot be fully ascertained
Fig. 7 Neuroprotective effects of CK-1δ inhibitors in ethacrynic acid pre-treated SH-SY5Y neuroblastoma cells. Neuroblastoma SH-SY5Y cells were
exposed to 20 μM EA for 12 h in the presence or in the absence of 5 μM of IGS-2.7 and IGS-3.27. a Number of viable cells after drug treatments
measured by the MTT assay. Each data point represents the mean ± SEM of three replications in four different experiments (*p < 0.05 significantly
different from SH-SY5Y untreated cells; †p < 0.05 and ††p < 0.01 significantly different from EA-treated cells). b Representative immunoblot showing
the levels of pTDP-43 protein before and after drugs treatment. c CDK6 protein levels assessed by Western blotting. Representative immunoblot is
shown. The densitometric data represent the mean ± SEM of 5 different experiments (*p < 0.05 and **p < 0.01 significantly different from SH-SY5Y
untreated cells; †p < 0.05 and ††p < 0.01 significantly different from EA-treated cells)
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Fig. 8 Effects of CK-1δ inhibitors on the subcellular localization of TDP-43 in ethacrynic acid pre-treated SH-SY5Yneuroblastoma cells. a Neuroblastoma
SH-SY5Y cells were seeded in coverslips and exposed to 20 μM EA for 12 h in the presence or in the absence of 5 μM of IGS-2.7 and IGS-3.27. TDP-43
protein localization was assessed by confocal laser scanning microscopy. Cells were stained with anti-TDP-43 antibody followed by secondary antibody
labeled with Alexa Fluor 488. DAPI (blue) and phalloidin (red) were used for nuclear or cytosolic staining respectively. b Quantitative
analyses of TDP-43 redistribution. Relative fluoresecence intensity of TDP-43 staining inside and outside nuclei were determined on 30
different cells from four separate fields, in each condition. Values are the mean ± SEM (magnification 63x). (**p < 0.01 significantly different
from SH-SY5Y untreated cells; ††p < 0.01 significantly different from EA-treated cells)
Table 1 Pharmacokinetic parameters of the CK-1δ inhibitor IGS2-7 in plasma and brain following a single intraperitoneal
(Dose: 2 mg.kg−1) and oral (Dose: 10 mg.kg−1) administration in male BALB/c mice
Route Matrix Tmax (h) Cmax (ng.ml
−1) AUClast (h.ng.mL
−1) AUCinf (h.ng.mL
−1) MRTlast (h) MRTinf (h)
i.p Plasma 0.5 224.51 1577 1689.27 6.07 7.87
Braina 1.0 670.56 3202.45 NR 3.40 8.64
p.o Plasma 0.5 1120.42 6692.81 6750.19 4.61 4.82
Braina 2.0 3940.51 23976.84 24232.22 4.73 4.99
NR not reported since AUCinf is 20 % greater than AUClast, MRT mean residence time
aBrain concentration and AUC expressed as ng.g−1 and h.ng.g−1 respectively
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with the present data. However our results indicate
that the well-known nuclear effect of TDP-43, indu-
cing repression of CDK6 expression [31] is blocked in
PGRN-deficient lymphoblasts. These results are in
consonance with a recent report indicating the loss in
brains of FTD/ALS individuals, of other nuclear
function of TDP-43 acting as splicing repressor of
nonconserved cryptic exons [38]. Thus loss of TDP-
43 nuclear functions may have pathogenic signifi-
cance. Interestingly, our data demonstrate that CK-1δ
inhibitors can rescue the nuclear transcriptional regu-
lation of CDK6 gene by preventing phosphorylation
and cytosolic exportation of the TDP-43 protein.
We didn’t observe significant differences between
c.709-1G > A mutation carriers, either asymptomatic or
with clinical signs of dementia, regarding proliferative
activity and cytosolic TDP-43 accumulation. However, it
was reported that clinically asymptomatic carriers show
poorer neuropsychological performance reflecting a
prodromal phase of the disease [39]. Because most of
the asymptomatic carriers are younger than the patients
it was suggested that these alterations might be early
manifestations of the disease. Thus it is tempting to
speculate that CK-1δ inhibitors could hopefully be useful
to slow disease progression in the early stages of disease.
Although FTLD-TDP-associated changes detected in
lymphoblasts from patients may reflect those occurring
in brain, it is also shown that our CK-1δ inhibitors, IGS-
2.7 and IGS-3.27, were also effective preventing death in
a neuronal cell model of induced TDP-43 phosphoryl-
ation with a concomitant decrease of TDP-43 phosphor-
ylation, TDP-43 cytosolic accumulation, and blocking
the increase in CDK6 levels.
Conclusion
Our data indicate that the brain penetrant CK-1δ inhibi-
tors are able to normalize the increased proliferation of
FTLD-TDP lymphoblasts and to prevent aberrant TDP-43
cytosolic accumulation. Considering the pathogenic role
of aberrant TDP-43 homeostasis and cell cycle control
failure in FTLD-TDP brain, it is suggested that CK-1δ
could be potentially a novel therapeutic target for the
treatment of FTLD-TDP and other TDP-43 proteinopa-
thies, with special mention to ALS, considering that a clin-
ical, genetic and neuropathological overlap exists between
FTLD-TDP and ALS. Moreover, the CK-1δ inhibitor, IGS-
2.7, with excellent pharmacokinetic properties, emerges as
a new drug candidate for the future treatment of neurode-
generative diseases where TDP-43 is involved.
Methods
Materials
All components for cell culture were obtained from
Invitrogen (Barcelona, Spain). The N-benzothiazolyl-2-
phenyl-acetamides derivatives, CK-1δ inhibitors, IGS-2.7
and IGS-3.27 were synthesized as previously described
(compound 20 and 46) [20]. The chemical structure, IC50
values regarding CK-1δ inhibition together with effective
permeability values, that predict their ability to cross the
blood brain barrier (BBB) assessed by PAMPA (Parallel
artificial membrane permeability assay) [40], are provided
in Table 2. In the PAMPA-BBB assay the permeability of
compounds IGS-2.7 and IGS-3.27 were compared with
that of 10 commercial clinical drugs for experiment
validation [20]. Ethacrynic acid was obtained from Sigma
(Alcobendas, Spain). Antibodies against human TDP-43
(10782-2-AP) and phospho (409/410)-TDP-43 (22309-
1AP) were obtained from Proteintech (Mancheser, UK).
Antibodies against CDK6 (sc-177), β-actin (sc-81178) and
α-tubulin (sc-23948) were obtained from Santa Cruz Bio-
technologies (Santa Cruz, CA, USA) and anti-LaminB1
was purchased from Calbiochem (Billerica, MA, USA).
Cell lines
Lymphoblastic cell lines
Peripheral blood samples of all the individuals enrolled in
this studio were taken after written informed consent of
the patients or their relatives (demographic information is
presented in Table 3) to establish the lymphoblastoid cell
lines as previously described [41], by infecting peripheral
blood lymphocytes with the Epstein Barr virus (EBV). All
study protocols were approved by the Donostia Hospital
and the Spanish Council of Higher Research Institutional
Review Board and are in accordance with National and
European Union Guidelines. Lymphoblastoid cells lines
were grown in suspension in T flasks in an upright pos-
ition, in approximately 8 ml of RPMI-1640 medium that
contained 2 mM L-glutamine, 100 μg/ml streptomycin/
penicillin and 10 % (v/v) fetal bovine serum (FBS) and
maintained in a humidified 5 % CO2 incubator at 37 °C.
Fluid was routinely changed every 3 days by removing the
medium above the settled cells and replacing it with an
equal volume of fresh medium.
Neuronal cell culture
The human neuroblastoma SH-SY5Y cell line was propa-
gated in Dulbecco’s Modified Eagle Medium (DMEM)
containing L-glutamine (2 mM), 1 % non-essential amino
acids, 1 % penicillin/streptomycin and 10 % fetal bovine
serum (FBS) under humidified 5 % CO2. On attaining
semiconfluence, cells were treated with ethacrynic acid
(EA) (20 μM) for 12 h. Some cultures were pretreated for
1 h with the CK-1δ inhibitors (5 μM). After treatment, cell
viability was assessed by MTT, pTDP-43 and CDK6 levels
by Western blotting and the subcellular localization of
TDP-43 was visualized under a confocal microscopy.
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Determination of cell proliferation, cell viability and cell cycle
Cell proliferation was determined by total cell counting,
using a TC10™ Automated Cell Counter, Bio-Rad
Laboratories, S.A. (Madrid, Spain). EBV-immortalized
lymphocytes from control and GRN mutation carriers
were seeded at an initial cell concentration of 1 × 106
cells × mL−1 and enumerated everyday thereafter. Cells
failing to exclude the dye were considered nonviable.
Cell viability was determined by the MTT assay (3-[4,5-
Dimethylthiazol-2-yl]-2,5-Diphenyltetrazolium Bromide),
as previously described [42]. Cell survival was esti-
mated as the percentage of the value of untreated
controls. Cell cycle phase distribution was routinely
determined by cell permeabilization followed by
propidium iodide (PI) staining and flow cytometry
analysis using an EPICS-XL cytofluorimeter (Coulter
Científica, Móstoles, Spain).
Immunoblotting analysis
To prepare whole-cell extract, cells were harvested,
washed in PBS and then lysed in ice-cold lysis buffer as
previously described [43]. To separate the cytosolic and
nuclear fractions, cells were harvested, washed in PBS
and then lysed in ice-cold hypotonic buffer as previously
described [44]. After extraction on ice for 15 min, 0.5 %
Nonidet P-40 was added and the lysed cells were centri-
fuged at 4,000 rpm for 10 min. Supernatants containing
cytosolic proteins were separated and pellets were resus-
pended in hypertonic buffer to lysate the nucleus [44].
The protein content of the extracts was determined by
the Pierce BCA Protein Assay kit (Thermo Scientific).
50–100 μg of protein were fractionated on a SDS poly-
acrylamide gel, and transferred to Poly (vinylidene) fluor-
ide (PVDF) membranes (Millipore, Billerica, MA, USA).
The membranes were then blocked with 5 % Bovine
Serum Albumin (BSA) (Sigma) and incubated, overnight
at 4 °C, with primary antibodies in the following concen-
trations, TDP-43 (1:1000); phospho-(S409/410)-TDP-43
(1:500); CDK6 (1:1000); β-actin (1:500); α-tubulin (1:1000)
and Lamin B1 (1:1000). Signals from the primary
antibodies were amplified using species-specific antisera
conjugated with horseradish peroxidase (Bio-Rad) and
detected with a chemiluminiscent substrate detection sys-
tem ECL. Protein band densities were quantified using
Image J software (National Institutes of Health, Bethesda,
Maryland, USA) after scanning the images with a GS-800
densitometer from Bio-Rad.
RNA preparation and quantitative real-time PCR
Total RNA was extracted from cell cultures using Trizol
reagent (Invitrogen, Alcobendas, Madrid, Spain). RNA
yields were quantified spectrophotometrically and RNA
quality was checked by the A260/A280 ratio and on a
1.2 % agarose gel to determine the integrity of 18S and
28S ribosomal RNA. RNA was then treated with DNase
Table 2 Overview of the compounds used in this study
Compound Structure % inhition CK-1δ IC50 [μM] Pe (10
−6 cm.s−1) BBB prediction
IGS-2.7
N
S NH
O
Cl
F3C
>60 0.023 ± 0.002 11.3 ± 2.0 CNS+
IGS-3.27
N
S NH
O
F3C
>60 0.047 ± 0.005 4.4 ± 2.9 CNS+
The % inhibition of CK-1δ activity was determined in vitro in presence of a fixed concentration of 10 μM of the compounds. IC50: half maximal concentration of
both compounds inhibiting CK-1δ activity. Pe: effective permeability (data from PAMPA assay). BBB prediction. Compounds were classified as CNS+ when they
present a permeability >3.74 × 10−6 cm · s−1 [20]. Values shown are the mean ± SD
Table 3 Characteristics of individuals enrolled in this study
c.709-1G > A mutation carriers
Control
n = 10
Asymptomatic
n = 12
FTLD patients
n = 7
Age (years) 51.8 ± 4.3 52.8 ± 4.3 65.3 ± 2.3
Sex, female, % (n) 50 % (5) 50 % (6) 100 % (7)
Age at onset - - 61 ± 0.6
Phenotype Asymptomatic Asymptomatic FTD-bv; CBS
Family history, % (n) 70 % (7) 54.5 % (6) 57.1 % (4)
Control: Individuals without sing of neurological degeneration; c.709-1G > A:
GRN mutation carriers; n: number of subjects. Values are expressed as mean ±
SEM. CBS Cortico-basal syndrome, FTD-bv Frontotemporal dementia (behavior)
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I Amplification Grade (Invitrogen, Alcobendas, Madrid,
Spain). One microgram was reverse transcribed with the
Superscript III Reverse Transcriptase kit (Invitrogen,
Alcobendas, Madrid, Spain). Quantitative real-time poly-
merase chain reaction (PCR) was performed in tripli-
cates using TaqMan Universal PCR MasterMix No
Amperase UNG (Applied Biosystems, Alcobendas,
Madrid, Spain) reagent according to the manufacturer’s
protocol. Real time quantitative PCR was performed in
the Bio-Rad iQ5 system using a thermal profile of an
initial 5-min melting step at 95 °C followed by 40 cycles
at 95 °C for 10 s and 60 °C for 60 s. Primers were
designed using the Universal ProbeLibrary for Human
(Roche Applied Science, Madrid, Spain) and used at a
final concentration of 20 μM. The sequences of the
forward and reverse primers used are the following: for
CDK6 5′-tgatcaactaggaaaaatcttggac-3′ and 5′-ggcaa-
catctctaggccagt-3′; for β-actin, 5’-ccaaccgcgagaagatga-3’
and 5’-ccagaggcgtacagggatag-3’. Relative messenger
RNA (mRNA) levels of the genes of interest were
normalized to β-actin expression using the simplified
comparative threshold cycle delta-delta CT method
(2-[ΔCT CDK6 -ΔCT Actin]).
Confocal laser scanning microscopy
Cells (1 × 106 × ml−1 for lymphoblast and 300,000 for
SH-SY5Y) were fixed for 30 min in 4 % paraformalde-
hyde in PBS, and blocked and permeabilized with 0.5 %
TritonX-100 in PBS-0.5 % BSA for 60 min at room
temperature. Then, cells were incubated overnight with
anti-TDP43 polyclonal antibody. After removing the pri-
mary antibody, cells were washed with PBS and incubated
with Alexa Fluor 488-conjugated anti-rabbit antibody
alone or in combination with phalloidin for cytoskeleton
staining. For nuclear staining, the preparations were
mounted on ProLong® Gold Antifade Reagent with DAPI
(Thermo Fisher) and visualized with the LEICA TCS-SP5-
AOBS confocal microscope system (Heidelberg,
Germany). Quantification of TDP-43 was performed using
Image J software. Data is expressed as the ratio of the
fluorescence intensity of cytosolic TDP-43 vs the intensity
of the fluorescence of the nuclear protein.
Pharmacokinetic in vivo study
A group of 48 male BALB/c mice (8–12 weeks old)
weighting between 25 and 35 g following a single intraper-
itoneal (i.p) and oral dose (o.p) administration were used
following the guidelines of the Institutional Animal Ethics
Committee (IAEC). Mice were divided into two groups
(Group 1: i.p. and Group 2: p.o.) with each group compris-
ing of 24 mice. Animals in Group 1 were administered
with derivative 11 solution formulation in 5 % NMP, 5 %
solutol HS in normal saline intraperitoneally at a dose
of 2 mg.Kg−1. The dosing volume administered was
10 mL.Kg−1. Animals in Group 2 were administered orally
with derivative 11 in suspension formulation in 0.1 %
Tween 80, 0.5 % NaCMC in water at a dose of 10 mg/Kg
through oral gavage using a 22-G oral feeding needle. The
dosing volume administered was 10 mL.Kg−1. Blood sam-
ples (approximately 60 mL) were collected from retro-
orbital plexus under light isoflurane anesthesia from retro
orbital plexus of three mice at each time point: 0.08, 0.25,
0.5, 1, 2, 4, 8 and 24 h (i.p.) and 0.25, 0.5, 1, 2, 4, 6, 8 and
24 h (p.o.). Samples were collected into labeled micro-
tubes, containing 20 % K2EDTA solution as an anticoagu-
lant. Plasma samples were separated from the whole blood
by centrifugation at 4000 rpm for 10 min at 4 ± 2 °C and
stored below −70 °C until bioanalysis. Immediately after
collection of blood, brain samples were collected from
each mouse at 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h (i.p.) and
0.25, 0.5, 1, 2, 4, 6, 8 and 24 h (p.o.). Brain samples were
homogenized using ice-cold phosphate buffer saline
(pH 7.4) and homogenates were stored below −70 °C until
analysis. All samples were processed for analysis by pro-
tein precipitation using acetonitrile. Concentrations of
IGS-2.7 in mouse plasma and brain samples were deter-
mined by fit-for-purpose LC-MS/MS method using the
following equipment and parameters: MS System Used:
AB Sciex API-4000; Software Version: Analyst 1.5; Ion
Source: Turbo spray; Mobile Phase: A: 0.1 % Formic acid
in acetonitrile, B: 10 mm Ammonium formate; Flow Rate:
0.8 mL/min; Column Used: Waters Xterra, 50 × 3.0, 5 μm.
The final bioanalytical method developed has a lower limit
of quantification (LLOQ) of 2.01 ng/mL in plasma and
10.07 ng/mL in brain. Non-Compartmental-Analysis tool
of Phoenix WinNonlin® (Version 6.3) was used to assess
the pharmacokinetic parameters. Peak plasma concentra-
tions (Cmax) and time for the peak plasma concentrations
(Tmax) were the observed values. The areas under the
concentration time curve (AUClast and AUCinf) were
calculated by linear trapezoidal rule. The terminal
elimination rate constant, k was determined by regression
analysis of the linear terminal portion of the log plasma
concentration time curve. MRT was calculated by using
formula as MRT =AUMCinf/AUCinf.
Statistical analysis
Statistical analyses were performed with Graph Pad Prism
6 (La Jolla, CA, USA). All the statistical data are presented
as mean ± standard error of the mean (SEM). Normality
was checked with the Shapiro-Wilk test. Parametric tests
were therefore used in the statistical analysis. Based on the
expertise achieved on previous works [21, 22] we can ex-
pect that, with the sample size we used and the signifi-
cance level we fixed, the variability within groups will be
low enough and the differences between groups to detect
will be high enough to ensure a statistical power above
0.9. Statistical significance was estimated by both one-way
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and two-way analysis of variance (ANOVA) followed by
the Bonferroni’s test for multiple comparisons. A value of
p < 0.05 was considered significant.
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